Clinical Trial: A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer

U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07796100) titled 'A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer' on Aug. 24.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of ZL-1310 in combination with a checkpoint inhibitor compared to standard first-line therapy in participants with Extensive-Stage Small Cell Lung Cancer.

Study Start Date: Dec. 31, 2026

Study Type: INTERVENTIONAL

Condition: Extensive-Stage Small Cell Lung Cancer

Intervention: COMBINATION_PRODUCT: ZL-1310 in combina...